Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 429-440

  Lafaille, Florian ^a   Solassol, Isabelle ^b   Enjalbal, Christine ^c   Bertrand, Benjamin ^b   Doulain, Pierre Emmanuel ^a   Vappiani, Johanna ^a   Bonnet, Pierre Antoine ^a   Deleuze Masquéfa, Carine ^a   Bressolle, Françoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c CNRS   (France)

Author keywords

Animal and human liver microsomes and hepatocytes; Anticancer agent; EAPB0503; LC ESI MS MS; Metabolite identification

Indexed keywords

1 (3' HYDROXYPHENYL) N METHYLIMIDAZO[1,2A ]QUINOXALIN 4 AMINE; 1 (3' HYDROXYPHENYL)IMIDAZO[1,2A ]QUINOXALIN 4 AMINE; 1 (3' METHOXYPHENYL)IMIDAZO[1,2A ]QUINOXALIN 4 AMINE; 1 (3' METHOXYPHENYL)N METHYLIMIDAZO[1,2A ]QUINOXALIN 4 AMINE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; EAPB 0502; EAPB 0503; EAPB 0602; EAPB 0603; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZATION; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMAL AND HUMAN LIVER MICROSOMES AND HEPATOCYTES; ANTICANCER AGENT; EAPB0503; LC-ESI-MS/MS; METABOLITE IDENTIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DEUTERIUM EXCHANGE MEASUREMENT; DOGS; HEPATOCYTES; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; QUINOXALINES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84886409773     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.09.015     Document Type: Article

References (15)

1. Moarbess G., Deleuze-Masquéfa C., Bonnard V., Paniagua S., Vidal J.R., Bressolle F., Pinguet F., Bonnet P.A. In vitro and in vivo antitumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg. Med. Chem. 2008, 16:6601-6610.
2. Moarbess G., El-Hajj H., Kfoury Y., El-Sabban M.E., Lepelletier Y., Hermine O., Deleuze-Masquéfa C., Bonnet P.A., Bazarbachi A. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase dependent apoptosis in T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Blood 2008, 111:3770-3777.
3. Deleuze-Masquéfa C., Moarbess G., Khier S., David N., Gayraud-Paniagua S., Bressolle F., Pinguet F., Bonnet P.A. New imidazo[1,2-a]quinoxaline derivatives synthesis and in vitro activity against human melanoma. Eur. J. Med. Chem. 2009, 44:3406-3411.
4. Khier S., Moarbess G., Deleuze-Masquéfa C., Margout D., Solassol I., Pinguet F., Bonnet P.A., Bressolle F.M.M. Quantitation of two imidazo[1,2-a]quinoxaline derivatives (EAPB0503 and EAPB0603) with anti-tumoral activity in human and rat plasma by liquid chromatography-electrospray mass spectrometry. Application to a Pharmacokinetic Study. J. Sep. Sci. 2009, 32:1363-1373.
5. Khier S., Deleuze-Masquéfa C., Moarbess G., Gattacceca F., Margout D., Solassol I., Cooper J.F., Pinguet F., Bonnet P.A., Bressolle F.M.M. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur. J. Pharm. Sci. 2010, 39:23-29.
6. Khier S., Gattacceca F., El Messaoudi S., Lafaille F., Deleuze-Masquéfa C., Bompart J., Cooper J.F., Solassol I., Pinguet F., Bonnet P.A., Bressolle F.M.M. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have anti-tumoral activity on melanoma and T-lymphomas. Drug Metab. Dispos. 2010, 38:1836-1847.
7. Lafaille F., Banaigs B., Inguimbert N., Enjalbal C., Doulain P.E., Bonnet P.A., Masquefa C., Bressolle F.M.M. Characterization of a new anticancer agent, EAPB0203 and its main metabolites: nuclear magnetic resonance and liquid chromatography-mass spectrometry studies. Anal. Chem. 2012, 84:9865-9872.
8. Guidance for Industry: Safety Testing of Drug Metabolites 2008, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf (assessed March 2013).
9. Guideline on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals 2009, http://www.ema.europa.eu/pdfs/vet/vich/46310409en.pdf (assessed March 2013).
10. Jia L., Liu X. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab. 2007, 8:822-829.
11. C. Masquéfa, G. Moarbess, P.A. Bonnet, F. Pinguet, A. Bazarbachi, F. Bressolle, Patent Corporation Treaty, European Patent 2008/063290 (2008).
12. Isom H.C., Georgoff L. Quantitative assay for albumin-producing liver cells after simian virus 40 transformation of rat hepatocytes maintained in chemically defined medium. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6378-6382.
13. Klieber S., Torreilles F., Guillou F., Fabre G. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction. Methods Mol. Biol. 2010, 640:295-308.
14. Fabre G., Rahmani R., Placidi M., Combalbert J., Covo J., Cano J.P., Coulange C., Ducros M., Rampal M. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem. Pharmacol. 1988, 37:4389-4397.
15. Chen J., Yuan T., Hao W., Cai M. Simple and efficient CuI/PEG-400 system for hydroxylation of aryl halides with potassium hydroxide. Catal Commun 2011, 12:1463-1465.